Franciane Paul
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Franciane Paul.
Gene | 2015
Franciane Paul; Sandra Pellegrini; Gilles Uzé
The human interferon α2 (IFNα2) was the first highly active IFN subtype to be cloned in the early eighties. It was also the first IFN and the first cytokine to be produced and commercialized by the pharmaceutical industry. Ipso facto it became the favorite IFNα subtype for academic researchers. For this fortunate reason IFNα2 has been at the origin of most discoveries related to the mechanism of action of type I interferons.
Cancer Research | 2018
Anje Cauwels; Sandra Van Lint; Franciane Paul; Geneviève Garcin; Stefaan De Koker; Alexander Van Parys; Thomas Wueest; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Elke Rogge; Annick Verhee; Bart Vandekerckhove; Niko Kley; Gilles Uzé; Jan Tavernier
An ideal generic cancer immunotherapy should mobilize the immune system to destroy tumor cells without harming healthy cells and remain active in case of recurrence. Furthermore, it should preferably not rely on tumor-specific surface markers, as these are only available in a limited set of malignancies. Despite approval for treatment of various cancers, clinical application of cytokines is still impeded by their multiple toxic side effects. Type I IFN has a long history in the treatment of cancer, but its multifaceted activity pattern and complex side effects prevent its clinical use. Here we develop AcTakines (Activity-on-Target cytokines), optimized (mutated) immunocytokines that are up to 1,000-fold more potent on target cells, allowing specific signaling in selected cell types only. Type I IFN-derived AcTaferon (AFN)-targeting Clec9A+ dendritic cells (DC) displayed strong antitumor activity in murine melanoma, breast carcinoma, and lymphoma models and against human lymphoma in humanized mice without any detectable toxic side effects. Combined with immune checkpoint blockade, chemotherapy, or low-dose TNF, complete tumor regression and long-lasting tumor immunity were observed, still without adverse effects. Our findings indicate that DC-targeted AFNs provide a novel class of highly efficient, safe, and broad-spectrum off-the-shelf cancer immunotherapeutics with no need for a tumor marker.Significance: Targeted type I interferon elicits powerful antitumor efficacy, similar to wild-type IFN, but without any toxic side effects. Cancer Res; 78(2); 463-74. ©2017 AACR.
Nature Communications | 2014
Geneviève Garcin; Franciane Paul; Markus Staufenbiel; Yann Bordat; José Van der Heyden; Stephan Wilmes; Guillaume Cartron; Florence Apparailly; Stefaan De Koker; Jacob Piehler; Jan Tavernier; Gilles Uzé
Archive | 2013
Jan Tavernier; Gilles Uzé; Guillaume Cartron; Franciane Paul; Jacob Piehler
Archive | 2016
Jan Tavernier; Lennart Zabeau; Gilles Uzé; Franciane Paul; Yann Bordat; Geneviève Garcin
Archive | 2014
Jan Tavernier; Jennyfer Bultinck; Sarah Gerlo; Gilles Uzé; Franciane Paul; Yann Bordat
Cytokine | 2013
Geneviève Garcin; Franciane Paul; Markus Staufenbiel; Yann Bordat; José Van Der Heyden; Stephan Wilmes; Guillaume Cartron; Florence Apparailly; Stefaan De Koker; Jacob Piehler; Jan Tavernier; Gilles Uzé
La Revue du praticien | 2010
Franciane Paul; Jean-François Rossi; Guillaume Cartron
OncoImmunology | 2018
Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Cancer Research | 2018
Jan Tavernier; Anje Cauwels; Sandra Van Lint; Franciane Paul; Geneviève Garcin; Alexander Van Parys; Nikolai Kley; Gilles Uzé